TP53 and breast cancer: This may be related to the finding by previous studies that ER + tumours from Asian breast cancer patients have higher frequencies of TP53 somatic mutations compared to ER + tumours from Western studies, although the mechanism behind this population-specific effect, whether genetic or environmental, remains to be elucidated [13, 29].